What Buyers Look For in a Psychiatry Practice (2026)

Psychiatry Practices

What Buyers Look For When Evaluating Your Psychiatry Practice in 2026

By the time a serious buyer signs a non-disclosure agreement on your psychiatry practice, they already know roughly what they think it's worth. What happens next — the diligence process — isn't really about discovering the practice. It's about confirming that the practice the seller described is the practice that actually exists. Every gap they find between the story and the reality moves the offer down, sometimes by a multiple turn, sometimes by killing the deal entirely.

Understanding what buyers look for when evaluating your psychiatry practice — before you go to market — is the difference between a smooth process at full price and a painful re-trade two weeks before signing. In 2026, with private equity-backed psychiatry platforms running sophisticated, repeatable diligence playbooks, the bar is higher than it has ever been.

This guide takes you inside the buyer's evaluation: the eight categories every institutional psychiatry buyer examines, the specific data and documents they expect to see, the red flags that automatically pull offers lower, and the moves a well-prepared owner can make to come through diligence at — or above — the headline number.

Tony Siebel — Founder & Managing Director, Olympic M&A

Top 50 M&A Advisors 2025 · $70M+ in completed healthcare M&A transactions · 60+ published articles on healthcare consolidation · Specialized advisor for psychiatry practice sellers

How Psychiatry Practice Buyers Actually Evaluate a Deal

Institutional psychiatry buyers — platforms like LifeStance, Mindpath Health, Talkiatry, ARC Health, and the regional consolidators behind them — don't evaluate practices the way most owners assume. They aren't looking for a "good practice" in the abstract. They're underwriting a specific economic outcome: a defensible cash flow stream they can integrate into their platform, grow, and exit at a higher multiple in 4–7 years.

That means everything they evaluate ladders up to four questions:

Are the earnings real and defensible? (Quality of earnings)
Will the earnings transfer to us when the seller leaves? (Provider concentration, transition risk)
Can we grow the earnings under our ownership? (Growth runway, service-line expansion, telepsychiatry, payer leverage)
What hidden risks could destroy the earnings? (Compliance, payer, real estate, clinical, regulatory, talent)

Every line item in their diligence list answers one of those four questions. Once you understand that, you can prepare your practice to give the right answer to every one of them.

The Eight Diligence Categories Buyers Examine in a Psychiatry Practice

1. Financial Diligence — The Quality of Earnings Review

This is the most important category, and the one most psychiatry sellers underestimate. A formal Quality of Earnings (QoE) review is now standard on virtually every psychiatry deal above $2M in enterprise value. The buyer's accounting firm will rebuild your trailing 36 months of earnings from scratch — bank statements, tax returns, payroll registers, payer remittances, EHR encounter data — and compare what they find to what you reported.

What they expect to see:

Three years of accrual-basis (or cleanly converted) financial statements
Monthly P&Ls reconciled to bank statements
Federal and state tax returns matching the books
A documented add-back schedule for owner compensation, personal expenses, and one-time items
Payroll registers tying to the financials
A trial balance and chart of accounts that supports clean reporting
Provider-level productivity reports tying to revenue

What kills deals here:

Cash-basis books with no accrual conversion
Add-backs the seller can't substantiate with documents
Owner expenses commingled and undocumented
Material discrepancies between books, tax returns, and bank statements
Aggressive revenue recognition (booking visits before collection without history to support)

If your books aren't ready for QoE today, the single most valuable investment you can make pre-sale is a fractional CFO engagement to clean them. The cost — typically $30K–$80K over 12 months — is recovered many times over in the multiple uplift it produces.

LEARN MORE — Preparing Your Psychiatry Practice for Sale

The complete preparation guide with the specific steps that protect your psychiatry practice value.

2. Clinical and Provider Diligence

Buyers spend significant diligence time on the clinical organization itself, because in psychiatry, the providers are the practice.

What they expect to see:

A complete provider roster with credentials, board status, state licensure, DEA registration, and malpractice coverage
Provider-level productivity (encounters, RVUs, collections) for the trailing 24 months
A clear picture of how revenue is distributed across providers (founder concentration analysis)
Clinical workflow documentation — intake, medication management cadence, therapy integration, controlled substance protocols
Patient panel size, new-patient wait times, no-show rates
Quality metrics where available (PHQ-9, GAD-7 tracking; outcomes data; readmission rates if applicable)

What kills deals here:

A single provider (usually the owner) producing 65%+ of revenue with no transition plan
Lapsed licensure, expired DEA registration, or open state board investigations
Malpractice claims history that isn't disclosed up front
Provider compensation structures the buyer can't continue post-close (above-market base, undocumented bonuses)
Key clinicians who haven't been told about the sale and may walk

The provider-concentration question is the single most important one in this category. Buyers will ask explicitly: "If the founding psychiatrist retired tomorrow, what percentage of revenue would survive the next 12 months?" Your job, well before going to market, is to make that answer comfortable for the buyer.

LEARN MORE — Psychiatry Practice Valuation: What Drives Value In 2026

A deeper walkthrough of how the EBITDA number itself gets built.

3. Payer, Revenue Cycle, and Coding Diligence

Buyers will evaluate the quality, durability, and concentration of your revenue.

What they expect to see:

A payer-mix report by collections for the trailing 24 months
A contracted-rate schedule by CPT code for each major payer
A revenue cycle dashboard (days in A/R, denial rates, first-pass payment rates)
Coding pattern analysis — are E/M codes (99213, 99214, 99215) and add-on psychotherapy codes (90833, 90836, 90838) being coded correctly and consistently?
Documentation supporting medical necessity for high-acuity codes
A clear picture of any value-based or alternative payment arrangements

What kills deals here:

One payer above 35% of revenue without a credible diversification path
Coding patterns that suggest upcoding (a 99215 distribution far above AMA CPT benchmarks without medical-necessity documentation to support it)
Out-of-network reliance with declining patient volume
Excessive denial rates or aged A/R indicating revenue cycle weakness
Significant payer rate cuts pending or recently announced that haven't been disclosed

Buyers will commission a coding audit on most psychiatry deals above $5M. If your coding distribution is more aggressive than your documentation supports, expect an offer adjustment.

4. Compliance, Regulatory, and Licensure Diligence

Psychiatry sits at one of the most regulated intersections in healthcare — controlled substances, behavioral health parity, state-by-state telepsychiatry rules, HIPAA, and corporate practice of medicine all converge here. Buyers know this and they look hard at compliance.

What they expect to see:

All providers' active state licensure, DEA registration, and any required state controlled-substance registrations
HIPAA compliance documentation — risk assessments, training logs, business associate agreements, breach notification history
Compliant controlled substance prescribing policies, especially for telepsychiatry across state lines
Corporate practice of medicine structure documentation if the buyer is a non-physician entity (PE platform structure with a friendly PC/MSO model)
State-specific telehealth licensure and prescribing compliance
42 CFR Part 2 confidentiality compliance where applicable
E/M and psychotherapy documentation samples that support the coding pattern

What kills deals here:

Open state board complaints or DEA inquiries
Lapsed or improperly maintained state licensure
HIPAA breach history that wasn't reported or remediated
Telepsychiatry prescribing across state lines without proper credentialing
Controlled substance prescribing patterns that don't have documented clinical justification
Corporate structure that doesn't comply with state corporate-practice-of-medicine rules

Compliance issues are the most common deal-killer in psychiatry M&A. Address every open matter — fully, in writing, with attorney sign-off — before you launch the process.

5. Technology, EHR, and Data Diligence

In 2026, the buyer is acquiring not just your practice but the data about your practice. The quality of your EHR and the structured data it produces directly affects diligence and post-close integration value.

What they expect to see:

A modern, interoperable EHR with structured data fields for diagnoses, medications, encounter types, and billing
Patient demographic and clinical data exportable in standard formats
Telepsychiatry platform integration with documented workflows
Cybersecurity posture — endpoint protection, MFA, encrypted backups, incident response policy
Practice management system tied to the EHR with clean billing and scheduling data
A current technology inventory — hardware, software licenses, vendor contracts

What kills deals here:

Paper charts or hybrid paper/electronic systems
A heavily customized legacy EHR the buyer can't migrate
Unstructured documentation that can't be analyzed (everything in free-text notes)
Cybersecurity gaps — no MFA, unencrypted backups, no incident response plan
Unlicensed or out-of-compliance software

6. Operational and Real Estate Diligence

The physical and operational footprint of the practice matters more than most owners realize.

What they expect to see:

A current organizational chart with reporting lines
Job descriptions and compensation for all non-provider staff
Lease documents for every site (or owned-real-estate detail with a fair-market lease analysis if the seller owns the building)
Vendor contracts (EHR, billing, lab, telepsychiatry, payment processing, malpractice)
Operational KPIs — visit volume, schedule utilization, no-show rate, new-patient wait time
Workflows for intake, scheduling, medication management, controlled substance refills, and crisis response

What kills deals here:

A long-dated lease at well-above-market rates the seller owns (related-party issue that needs cleanup)
A lease expiring in <12 months with no renewal option
Key non-provider staff (practice manager, billing lead) with no documented compensation or no continuation plan
Vendor contracts the buyer can't assign or terminate cleanly

7. Legal, Insurance, and Tax Diligence

Buyers will examine every legal exposure attached to the practice.

What they expect to see:

Corporate organizational documents (operating agreement, bylaws, cap table)
All contracts (employment, independent contractor, payer, vendor, lease, lender)
Litigation and claims history for the practice and each provider (including malpractice)
Tax returns for the past 3–5 years with no unresolved audit issues
Insurance certificates — malpractice (claims-made vs. occurrence, tail coverage planning), general liability, cyber, employment practices
Any restrictive covenants that may bind providers post-close

What kills deals here:

Unresolved litigation or undisclosed claims
Malpractice tail coverage that isn't planned or funded
Non-compete or non-solicit issues that could prevent providers from staying or leaving
Tax issues (unfiled returns, open audits, unpaid liabilities)
A cap table that doesn't match the corporate documents

8. Growth and Strategic Diligence

Finally, buyers underwrite the future. They want to see a credible path to growing the EBITDA they're acquiring.

What they expect to see:

A documented growth plan for the next 24 months
Telepsychiatry expansion roadmap (additional state licensure, hours, capacity)
Service-line expansion plans (TMS, Spravato, long-acting injectables, integrated therapy)
Recruiting pipeline for additional psychiatrists or psychiatric NPs
Marketing and referral channel performance data
Payer contract renewal schedule and renegotiation opportunities

What kills deals here:

Download — 2026 Psychiatry Practice Market Update — Free

Current buyer activity, deal terms, and the diligence priorities shaping psychiatry M&A right now.

Five Red Flags That Pull Offers Lower in Psychiatry Diligence

1. A founder above 65% of revenue with no transition plan or successor providers.

The buyer doesn't see a practice; they see a job.

2. Recent, unexplained drops in new-patient volume.

Even a 10% dip in trailing-six-month new-patient adds will trigger questions. Get ahead of the explanation in your management presentation.

3. A sole reliance on the founder's referral relationships.

Buyers want diversified, documented referral sources. A practice that depends on personal physician-to-physician relationships the founder built over decades is a transition-risk practice.

4. Above-market provider compensation.

The buyer will model the post-close compensation reset, but they'll also model the risk that providers leave. An offer is rarely full multiple on EBITDA the buyer doesn't believe will hold.

5. A "we'll fix it later" attitude on compliance gaps.

The fastest way to lose buyer confidence is to surface a compliance issue and tell the buyer their team can address it post-close. Address it pre-close, fully, with documentation.

How to Prepare for Buyer Diligence — The 18-Month Playbook

The owners who consistently come through diligence at full price are the ones who treat the 18 months before launch as the work itself. Here's the rough sequence we run with psychiatry clients:

Months 18–13: Move to accrual accounting, engage a fractional CFO, begin building the 36-month add-back schedule. Audit provider-level productivity and payer-mix data. Identify the one or two highest-impact pre-sale moves (additional psychiatrist hire, payer renegotiation, telepsychiatry expansion).

Months 12–7: Execute on the highest-impact moves. Recruit and onboard the additional clinician. Renegotiate underpriced payer contracts. Lift telepsychiatry mix. Build or scale TMS or Spravato programs. Begin assembling the data room.

Months 6–3: Final QoE rehearsal with the fractional CFO. Resolve every open compliance, licensure, and legal matter. Tail coverage planning. Lease cleanup. Provider compensation normalization where needed.

Months 3–0: Engage your M&A advisor. Build the CIM and management presentation. Finalize the data room. Launch.

The owners who skip this work and try to compress it into 90 days almost always leave money on the table — and many leave a deal on the table.

LEARN MORE — Preparing Your Psychiatry Practice for Sale

The complete preparation guide with the specific steps that protect your psychiatry practice value.

LEARN MORE — Why Private Equity Firms Buy Psychiatry Practices

The insider perspective on what PE firms specifically look for in psychiatry — and what that means for your valuation.

How Olympic M&A Prepares Psychiatry Practices for Diligence

When we engage with a psychiatry practice owner 12–24 months pre-sale, we don't wait for diligence to start — we run a mock diligence against the practice early in the engagement, find every gap a real buyer would find, and close those gaps before the practice ever sees a buyer NDA.

Our pre-diligence readiness work for psychiatry practices includes:

Mock QoE with a healthcare-specialized accounting firm
Add-back schedule construction with full source documentation
Compliance and licensure audit across DEA, state board, HIPAA, and 42 CFR Part 2
Coding and revenue-cycle audit including CPT distribution analysis
Provider concentration and transition planning
Real estate, lease, and related-party cleanup
Data room construction organized to the diligence categories above
Management presentation development that anticipates and addresses every diligence question

By the time we take a prepared psychiatry practice to market, the diligence answers are already in the data room, and the buyer's diligence team is confirming what we showed them — not discovering surprises. That's how deals close at full price.

LEARN MORE — How to Sell a Psychiatry Practice — The Complete Guide

The full step-by-step framework on bringing your practice to market.

LEARN MORE — Psychiatry Practice EBITDA Multiples

Current multiple ranges by practice profile.

Frequently Asked Questions About What Buyers Look For in a Psychiatry Practice

What is the most important thing buyers look for in a psychiatry practice?

Defensible, transferable earnings. Buyers can model the upside of nearly any practice — but they only pay full multiple when they believe the trailing earnings are real, well-documented, and will survive the seller's exit. That's why provider concentration, quality of earnings, and clean financial documentation are the three most important factors in nearly every psychiatry deal.

How long does psychiatry practice diligence take?

Typically 60–120 days from signed letter of intent to close. Well-prepared practices close on the shorter end of that range; practices that surface issues in diligence stretch to the long end or beyond. The single biggest determinant is whether the data room and QoE answers are ready at LOI signing.

What's a Quality of Earnings (QoE) review and do I need one?

QoE is a buyer-commissioned accounting review that rebuilds your trailing earnings from primary documents (bank statements, tax returns, payer remittances) to confirm the EBITDA the buyer is paying for. On any psychiatry deal above $2M in enterprise value, expect QoE. On larger deals, you may benefit from commissioning your own sell-side QoE before launch to identify and address gaps proactively.

What compliance issues most often kill psychiatry deals?

Lapsed or improperly maintained DEA registration; open state medical board complaints; controlled substance prescribing patterns without documented clinical justification; HIPAA breach history that wasn't reported or remediated; and telepsychiatry prescribing across state lines without proper credentialing. Address every one of these before launch.

How much provider concentration is too much?

Buyers grow uncomfortable when any single provider exceeds 50% of revenue, and seriously discount practices where the founder is above 65%. The structural target before launch is no provider above 40% of revenue — though the path to get there from a solo or near-solo practice typically requires 18–24 months of recruiting and ramp.

Should I tell my staff and providers about a potential sale?

Not until your advisor tells you to. Premature disclosure can create real instability — providers exploring other roles, staff turnover, patient anxiety. Most psychiatry deals run with a tight "deal team" (typically the owner, finance lead, and outside advisors) until LOI, with broader staff communication scripted for after the LOI is signed. Your advisor will help you sequence this carefully.

What's the single best thing I can do to prepare for buyer diligence?

Build a clean, complete, organized data room before you launch. The data room is the document buyers form their early impressions on. A complete, professional data room signals that the practice is professionally managed and dramatically shortens the diligence timeline — which directly protects your deal's certainty of close.

About Tony Siebel

Founder & Managing Director, Olympic M&A

Tony Siebel is the Founder & Managing Director of Olympic M&A and one of the country's most active healthcare practice M&A advisors. Named to the Top 50 M&A Advisors of 2025, Tony has personally led more than $70M in completed healthcare M&A transactions and authored 60+ articles on healthcare practice valuation, sale readiness, and structured competitive sale processes.

Tony's expertise in the psychiatry and TMS industry is unparalleled. He understood our practice, our patients, and our growth story — and ran a process that delivered a result well above what other advisors had quoted us. He is the advisor I recommend to any psychiatrist thinking about a sale.

— Brian E., MD · Psychiatry Practice Owner

Tony advises psychiatry practice owners across the U.S. on practice valuation, sale preparation, buyer selection, and deal execution — always with the same goal: a confidential, competitive process that delivers the best possible outcome for the owner and the practice.

olympicma.com | tonys@olympicma.com | 502.360.8320

Join the Webinar — The Truth About Selling Your Psychiatry Practice in 2026–2027

A live, confidential webinar for psychiatry practice owners exploring what comes next. Insider perspective on valuation, buyer types, and how to protect what you've built. No pressure, no prep needed.